Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

American Journal of Surgery

Volumn 196, Issue 4, 2008, Pages 505-511

  Christante, Dara ^a   Pommier, SuEllen ^a   Garreau, Jennifer ^a   Muller, Patrick ^a   LaFleur, Brett ^a   Pommier, Rodney ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Breast cancer; Hormone replacement therapy; Medroxyprogesterone

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 52049092991     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.06.023     Document Type: Article

References (19)

1. Cheek J., Lacy J., Toth-Fejel S., et al. The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137 (2002) 1015-1019
2. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289 (2003) 3243-3253
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997) 1047-1059
4. Anderson G.L., Chlebowski R.T., Rossouw J.E., et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55 (2006) 103-115
5. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. Am J Statistics 53 (1958) 457-481
6. Hardin C., Pommier R., Calhoun K., et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg 31 (2007) 1041-1046
7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
8. Adjuvant! Online. Accessed May 26, 2008. http://www.adjuvantonline.com
9. Schuetz F., Diel I.J., Pueschel M., et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196 (2007) 342e1-342e9
10. In: Ries L.A.G., Young J.L., Keel G.E., et al. (Eds). SEER Survival Monograph: Cancer Survival Among Andults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics (2007), National Institutes of Health, Bethesda, MD
11. Bonnier P., Bessenay F., Sasco A.J., et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79 (1998) 278-282
12. Manjer J., Malina J., Berglund G., et al. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 92 (2001) 919-922
13. Biglia N., Sgro L., Defabiani E., et al. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 31 (2005) 467-472
14. Sacchini V., Zurrida S., Andreoni G., et al. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9 (2002) 266-271
15. In: Greene F.L., Page D., and Fleming I.D. (Eds). AJCC Cancer Staging Manual. Ed 6 (2002), Springer, New York, NY
16. Antoine C., Liebens F., Carly B., et al. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod 19 (2004) 741-756
17. Planas-Silva M.D., Waltz P.K., and Kilker R.L. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant. J Steroid Biochem Mol Biol 98 (2006) 193-198
18. Lewis J.S., Osipo C., Meeke K., et al. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94 (2005) 131-141
19. Prempro (2007), Wyeth, Philadelphia, PA [package insert]